{
  "report_rows": [
    {
      "kpi": "Total Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.75B vs. cons ~$1.72B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$0.78 vs. cons ~$0.745",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "TAVR Segment Sales",
      "prediction": "BEAT",
      "answer": "pred ~$1.25B vs. cons ~$1.22B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Total Revenue Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$6.75B vs. cons ~$6.72B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Adjusted EPS Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$3.02 vs. cons ~$3.00 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 TAVR Constant-Currency Growth Guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~8% vs. cons ~8% (FY2026, 7-9% range reaffirmed)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 3.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 5.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "Stock fell ~11% into the print on sector-wide TAVR sentiment (Medtronic commentary) and an unrelated FTC penalty headline, not company-specific fundamentals. A modest Q2 beat with reaffirmed/slightly raised FY26 guide (revenue, EPS) and continued TAVR/TMTT momentum should validate that the selloff was overdone, prompting sell-side price-target reiterations/upgrades (avg PT ~$97-98 vs ~$84 current) over the following days as analysts digest TMTT trajectory, CMS NCD commentary, and new CFO's tone, pulling the stock back toward pre-selloff highs. Risk to follow-through is the flagged tougher H2 comps capping the magnitude of upward estimate revisions.",
  "day5_confidence": "LOW"
}